AgeX Therapeutics, Inc. (AGE) News
Filter AGE News Items
AGE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AGE News Highlights
- For AGE, its 30 day story count is now at 2.
- Over the past 16 days, the trend for AGE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about AGE are III and ST.
Latest AGE News From Around the Web
Below are the latest news stories about AGEX THERAPEUTICS INC that investors may wish to consider to help them evaluate AGE as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to start off the final day of the trading week with a breakdown of the biggest pre-market stock movers for Friday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of all the biggest pre-market stock movers worth reading about on Thursday! |
AgeX Therapeutics Reports First Quarter 2023 Financial ResultsALAMEDA, Calif., May 12, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023. |
AgeX Therapeutics Receives Stock Exchange Deficiency LetterALAMEDA, Calif., April 26, 2023--AgeX Therapeutics , Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has st |
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial ResultsALAMEDA, Calif., March 31, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022. |
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing RequirementsALAMEDA, Calif., November 25, 2022--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of the NYSE American (the "Exchange") that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Sectio |
AgeX Therapeutics Reports Third Quarter 2022 Financial ResultsALAMEDA, Calif., November 10, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2022. |
AgeX Therapeutics Reports Second Quarter 2022 Financial ResultsALAMEDA, Calif., August 12, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022. |